https://www.zacks.com/commentary/2257574/top-stock-reports-for-nvidia-alphabet-johnson-johnson?cid=CS-ZC-FT-research_daily-2257574
Apr 18, 2024 - Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
zc:-5701486144601971551
0
https://www.zacks.com/stock/news/2256185/j-j-jnj-q1-earnings-beat-estimates-sales-miss-medtech-soft?cid=CS-ZC-FT-analyst_blog|earnings_article-2256185
Apr 16, 2024 - J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.
zc:3295188397576504498
0
https://www.zacks.com/stock/news/2256163/housing-numbers-shrink-as-q1-earnings-heat-up-bac-jnj-unh?cid=CS-ZC-FT-ahead_of_wall_street-2256163
Apr 16, 2024 - Both Housing Starts and Building Permits missed expectations, while BofA, J&J and UnitedHealth all beat on earnings.
zc:4065324700030427204
0
https://seekingalpha.com/news/4089736-jnj-q1-earnings-preview-a-lot-of-moving-factors-expected-to-bring-in-line-results?source=feed_sector_healthcare
Apr 15, 2024 - Johnson & Johnson (JNJ) is set to announce Q1 earnings results, and analysts expect a profit of $2.65 (-1.1% Y/Y) on revenue of $21.39B (-13.4% Y/Y).
0
sa:-8438550471494336466
0
https://www.zacks.com/stock/news/2254814/3-quarterly-releases-to-watch-next-week?cid=CS-ZC-FT-stocks_in_the_news-2254814
Apr 12, 2024 - Earnings season is always an exciting time for investors, with companies finally revealing what's transpired behind closed doors. And concerning next week's docket, these three notable companies are scheduled to report.
zc:3650594170285313589
0
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
zc:5776039764262460316
0
https://www.zacks.com/stock/news/2253845/unlocking-q1-potential-of-johnson-johnson-jnj-exploring-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2253845
Apr 11, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
zc:1288384018134729588
0
https://www.zacks.com/stock/news/2252668/johnson-johnson-jnj-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2252668
Apr 09, 2024 - Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:6541271838676025771
0
https://www.zacks.com/stock/news/2252179/bristol-myers-bmy-gets-fda-nod-for-label-expansion-of-abecma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252179
Apr 08, 2024 - Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
zc:-2136049557520334469
0
https://www.fool.com/investing/2024/04/06/can-a-new-ceo-fix-boeing/?source=iedfolrf0000001
Apr 06, 2024 - We also talk with e.l.f. Beauty CEO Tarang Amin about how the company is succeeding.
0
fool:-5644472562978032325
0